TransEnterix: Betting on haptics
Transenterix’ Senhance surgical robotics system
TransEnterix (NYSE:TRXC) is betting that the haptics technology in its Senhance robot-assisted surgery platform will help it make headway against its competitors in the field.
Senhance, which TransEnterix acquired for $100 million last fall as the Telelap ALF-X device, is sold under the European Union’s CE Mark; the company is on track for an FDA decision next year, CEO ToddPope said.
It was a timely buy, as the company shelved its flagship SurgiBot last year after the FDA denied its submission for 510(k) clearance. Pope said the company is still working with the FDA on a plan for refiling for the SurgiBot.
Next>>
Video demonstration of the Senhance robotic surgery system
Tell Us What You Think!